•Next
generation Selective Estrogen Receptor Degraders (SERDs) developed from core
compound G1T48 (L/O
to G1 therapeutics, Phase 1/2)
to deliver next generation SERD with brain penetration
•Treatment
for TAM/AI-resistant breast cancer
•Strong
potential for treatment in ER+ metastatic breast cancer
•Opportunity
for combination with CDK4/6 inhibitors and PI3K inhibitors